XtalPi Holdings Announces 2026 Interim Results
SHENZHEN, China, Aug. 19, 2026 /PRNewswire/ -- Financial Highlights: In the first half of 2026, the Group recorded revenue of RMB393.6 million, compared with RMB517.1 million in the corresponding period of last year. The change was primarily attributable to the high base in the corresponding period of last...
ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights
The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care. JENA, Germany, Aug. 19, 2026 /PRNewswire/ -- ZEISS Medical Technology, one of the world's leading medical technology companies, today announced the 510k...
DrFirst Receives Frost & Sullivan’s 2026 North America Enabling Technology Leadership Recognition for Advancing AI-Enhanced Medication Orchestration
DrFirst is honored for redefining medication management with its scalable platform that embeds intelligence directly in prescribing, making it more efficient for providers, pharmacies, and patients. SAN ANTONIO, Aug. 19, 2026 /PRNewswire/ -- As healthcare organizations continue to navigate fragmented medication workflows, rising administrative complexity, and growing demands for faster patient access, DrFirst is transforming how prescriptions move from...
Sisram Medical Delivers Solid 2026 Interim Results
Injectables Business Fuels Rapid Growth as APAC Drives International Revenue Expansion HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today announced its unaudited consolidated interim results for the six...
Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum
SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to validate the global value of Hengrui's innovation portfolio. Financial Highlights In the first half of 2026, Hengrui reported...
Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Science is where the company starts; breakthroughs are what it...
So-Young to Report Second Quarter 2026 Financial Results on August 31, 2026
BEIJING, Aug. 19, 2026 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it will report its financial results for the second quarter ended June 30, 2026, before U.S. markets open on August 31, 2026. So-Young's management will...
Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care
Patients from Australia, India, Indonesia, South Korea and Singapore gathered at Edwards Lifesciences' annual APAC Patient Experience event to share their stories and help advance more patient-centered care. SINGAPORE, Aug. 19, 2026 /PRNewswire/ -- As structural heart disease continues to impact a growing number of people across Asia Pacific amid a...
NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product
WUXI, China, Aug. 19, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORROY's 68Ga-NYM096, a potential radiopharmaceutical imaging agent targeting carbonic anhydrase Ⅸ (CAⅨ) for PET...
MALAYSIA AND BANGLADESH TRANSLATE LEADERS’ COMMITMENT INTO HEALTHCARE COOPERATION
Health Ministry Seeks Affordable Malaysian Healthcare for Bangladeshi Patients DHAKA, Bangladesh, Aug. 19, 2026 /PRNewswire/ -- A delegation from Malaysia Healthcare Travel Council (MHTC), led by H.E. Mohd Shuhada Othman, High Commissioner of Malaysia to Bangladesh, met with H.E. Sardar Md. Sakhawat Husain, Honourable Minister of Health and Family Welfare of...
